Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Primary Myelofibrosis 1Polycythemia Vera 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Anemia, Aplastic 1

Interventions

Imatinib Mesylate 6Cytarabine 5ponatinib 4nilotinib 4venetoclax 3fludarabine phosphate 3Mycophenolic Acid 3thymoglobulin 2fludarabine 2enasidenib 2Methotrexate 2Lenalidomide 2Cyclosporine 2Cyclophosphamide 2Azacitidine 2Antilymphocyte Serum 2quizartinib 1methanesulfonic acid 1glasdegib 1etoposide phosphate 1daratumumab 1bosutinib 1asciminib 1Whole-Body Irradiation 1Transplantation 1Temozolomide 1Tacrolimus 1Stem Cell Transplantation 1Standard of Care 1RFT5-SMPT-dgA immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myeloid × methanesulfonic acid × Clear all
NCT01760655 2025-10-30

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Thomas Jefferson University

Phase 2 Completed
62 enrolled 15 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Hodgkin Disease, Leukemia, Myeloid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Polycythemia Vera, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡